PURPOSE: To study the efficacy and safety of a new sclerosing gel of absolute @entity1068 in the percutaneous treatment of @entity1211 ( @entity1211 ). MATERIALS AND METHODS: In this prospective, non-randomized multicenter study @entity1 with clinically and by magnetic resonance imaging diagnosed @entity1211 were treated. Efficacy and safety of the gel was evaluated. Therapeutic outcome was judged at day 56 after the last sclerosing therapy. Blood @entity1068 levels of @entity1068 were measured after each infusion. Local and systemic adverse events were recorded. RESULTS: Seventy-five (75) @entity1 (age 4-46 y, mean 26 y) were treated in 172 sessions. Compared to no treatment, @entity1068 gel showed a complete cure rate of about 15% per session (p<0.00001). At the end of the last session, therapeutic outcome was complete (score 2) and partial (score 1) in 28 (37%) and 42 @entity1 (56%), respectively, whereas treatment failure (score 0) was observed in 5 @entity1 (7%). The plasmatic @entity1068 levels were very low (mean  SEM 0.03  0.06 g L(-1)), with only one @entity1 above the legal 0.5 g L(-1) intoxication limit (0.6 g L(-1)). Forty-six (46) product-related adverse events (all local, none systemic) were reported. They included temporary mild @entity158 (N=21), inflammatory reactions (N=4), and local complications (7 skin necroses, 7 compressive @entity16 , 4 product leakage/fistula, 2 intralesional fibrous or granulomatous tissue, 1 dense node; 12.2% of the infusions). All local complications resolved spontaneously, except for 2 skin necroses requesting surgical paring. CONCLUSION: @entity1068 gel is an embosclerosing substance that provides high efficiency and improves safety of @entity1068 in the treatment of @entity66 .

Treatment of XXXX : first experience with a new sclerosing agent--a multicenter study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity66 :: ('MESH:D004194', 'Disease') :: ['VM lesions'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathies'] @entity158 :: ('MESH:D010146', 'Disease') :: ['isolated pain'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['VM', 'venous malformations'] @entity1068 :: ('MESH:D000431', 'Chemical') :: ['Ethanol', 'ethanol']
@entity1211 :: (MESH:D054556,Disease) :: ['venous malformations']
